Acute hepatitis after parenteral amiodarone administration

M PYE, R J NORTHCOTE, S M COBBE

From the University Department of Medical Cardiology, Royal Infirmary, Glasgow

SUMMARY Amiodarone is believed to have caused acute hepatitis 24 hours after intravenous administration in two patients in whom no other alternative cause of hepatitis was found.

Various extracardiac side effects have been reported after amiodarone treatment.^{1,2} Asymptomatic hepatic dysfunction was reported in 15-40% of patients on long term amiodarone treatment.³⁻⁵ These patients had increases in serum concentrations of transaminases of 1.5-4 times normal values.

We report two cases of acute hepatitis that developed 24 hours after intravenous amiodarone treatment. We found no other explanation for the hepatitis in these patients.

Case reports

PATIENT 1

A 48 year old woman (weight 50 kg) had undergone mitral and aortic valve replacement in 1982. She subsequently underwent repeat mitral valve replacement in February 1987. In May 1987 she was admitted as an emergency with a two month history of progressive dyspnoea, nausea, fatigue, and intermittent palpitation. She had been on long term treatment with frusemide, spironolactone, digoxin, and warfarin. On admission her blood pressure was 130/70 mm Hg, the jugular venous pressure was raised 6 cm, and she was peripherally well perfused. The apex beat was displaced and there was a soft apical systolic murmur. There was firm regular hepatomegaly (three fingerbreadths). Her electrocardiogram showed atrial fibrillation with a ventricular rate between 140 and 180 beats per minute. Her chest radiograph showed mild cardiomegaly with pulmonary vascular redistribution. Doppler examination confirmed moderate mitral regurgitation and tricuspid regurgitation.

The table shows the laboratory results. On day 1 she was started on verapamil 40 mg three times a day in addition to digoxin. This failed to control the

Requests for reprints to Dr M Pye, Department of Medical Cardiology, Royal Infirmary, Queen Elizabeth Building, 10 Alexandra Parade, Glasgow G31 2ER.

Accepted for publication 14 March 1988

Table Serum concentrations of hepatic enzymes and bilirubin in cases 1 and 2

Day	AP	AST	ALT	B	CK
Case 1 (50 kg)					
1	145	40	45	34	50
2	155	35	20	30	60
3	150	36	22	30	65
4 (amiodarone started)	185	40	28	30	70
5	150	720	580	65	55
6 (amiodarone stopped)	140	1860	1770	155	50
7	140	1010	1450	145	60
8	160	320	740	100	60
10	156	246	700	80	50
12	170	114	320	55	45
16	120	37	50	25	50
Case 2 (54 kg)					
1 am	200	67	15	10	366
2 pm	210	71	27	12	908
2	240	259	47	15	1760
4	250	90	60	12	240
6 (amiodarone started)	220	45	25	20	100
7	500	2400	1440	60	90
8 (amiodarone stopped)	600	2400	1600	40	110
9	500	980	1340	35	150
10	—	450	770	30	120
12	250	200	210	30	160
13 operation					

Normal ranges for: AP, alkaline phosphatase (80-280 IU/l); AST, aspartate transaminase (12-48 IU/l); ALT, alanine transaminase (3-55 IU/l); B, bilirubin (3-22 µmol/l); CK, creatine kinase (30-150 IU/l).

ventricular rate and was stopped on day 3. On day 4 she still had fast atrial fibrillation despite adequate concentrations of serum digoxin. Treatment with intravenous amiodarone was started. She was given a bolus of 300 mg followed by an infusion of 900 mg. On day 5 900 mg of amiodarone was given intravenously and 400 mg orally and on day 6 200 mg was given orally. There was no significant change in her clinical condition despite a considerable rise in the serum concentration of hepatic enzymes. Toxic hepatitis was suspected and amiodarone was stopped. Other treatment was not changed. Serum concentra-

Acute hepatitis after parenteral amiodarone administration

tions of hepatic enzymes fell 24 hours after amiodarone was stopped. There was no change in her clinical condition. Propranolol (20 mg three times a day) was started on day 8 and the ventricular rate was rapidly controlled. The patient subsequently underwent mitral valve replacement. Other laboratory tests, including haemoglobin, urea, electrolytes, and erythrocyte sedimentation rate were normal. Hepatitis A and B markers, viral studies, and anti-tissue antibodies were negative. Blood cultures were sterile.

PATIENT 2

A 70 year old woman (weight 54 kg) was admitted with an acute inferior myocardial infarction. She had a past history of hypertension, angina, hypothyroidism, and polymyalgia rheumatica. She was taking atenolol, nifedipine, prednisolone, and thyroxine on admission. She had clinical and radiological evidence of left ventricular failure, blood pressure was 110/60 mm Hg, jugular venous pressure was elevated 7 cm, and her extremities were cool. The apex beat was displaced and there was auscultatory evidence of mitral regurgitation. There was firm regular hepatomegaly (two fingerbreadths). Cardiac catheterisation showed evidence of pulmonary hypertension with a mean pulmonary capillary wedge pressure of 30 mm Hg, right atrial pressure of 14 mm Hg, and confirmed gross mitral regurgitation. She was treated initially with intravenous diuretics, sodium nitroprusside, and dobutamine 2.5 µg/kg/min. She remained unwell and on day 5 fast atrial fibrillation developed (160 beats/min). Intravenous amiodarone (300 mg) was given over 30 minutes, followed by 1200 mg over the next 24 hours. This dose (1200 mg/day intravenously) was continued until day 8 and then stopped because of an acute increase in the serum concentration of hepatic enzymes and once again a toxic hepatitis was suspected. Serum concentrations of hepatic enzymes fell rapidly when amiodarone was stopped. Her clinical condition remained poor and she underwent mitral valve replacement on day 12.

Discussion

Although we cannot exclude an alternative cause of hepatic dysfunction, we believe that the clinical course suggests that amiodarone was responsible for the development of acute hepatitis in these two patients.

Despite clinical evidence of cardiac failure both patients had normal concentrations of serum transaminases before the administration of amiodarone. There was no subsequent deterioration in their condition to account for the sudden increase in serum concentrations of transaminase or bilirubin. The suggestion that amiodarone caused the hepatitis is supported by rapid improvement in their liver func-

tion tests when amiodarone was stopped.

The increase in serum transaminases with long term amiodarone treatment was reversible and dose dependent, and did not require withdrawal of the drug.^{1,2,6} There have been only two previously reported cases of possible acute hepatitis after intravenous amiodarone.^{7,8} The mechanism of acute or chronic amiodarone hepatotoxicity is not known. There have been reports of both cytotoxic and cholestatic liver damage induced by amiodarone. It has been suggested that steatosis and alterations resembling alcoholic hepatitis or cholestatic hepatitis may represent short term side effects with oral treatment, whereas micronodular cirrhosis may be a long term side effect.⁹

The pattern of abnormalities in our patients is typical of hepatitis. Severe acute hepatic dysfunction with intravenous amiodarone is rarely reported and our two cases suggest that the liver is more susceptible to amiodarone toxicity when it is haemodynamically compromised or hypoxic.

Amiodarone is a popular antiarrhythmic agent because of its high efficacy in otherwise resistant arrhythmias and its freedom from any negative inotropic effects. In view of its widespread use, both intravenous and oral, it is important to be aware of any serious adverse reactions. We have reported these two cases to the Committee on the Safety of Medicines.

References

- 1 Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM. Side effects of longterm amiodarone therapy. *Circulation* 1983;67:45-51.
- 2 Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent drug refractory arrhythmias. *Circulation* 1983;68:88-94.
- 3 Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone: clinical efficacy and electrophysiology during longterm therapy for recurrent ventricular tachycardia or ventricular fibrillation *N Engl J Med* 1981;305:539-45.
- 4 McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. *Br Med J* 1983;287:175-80.
- 5 Planteux G, Heaghem C, Ernowald H, Vandeghen N. Longterm hepatic tolerance of amiodarone in the clinic. *Eur J Pharmacol* 1969;8:369-76.
- 6 McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. *Br Med J* 1983;287:175-80.
- 7 Lupon-Roses J, Simo-Canonge R, Lu Cortez L, Permyer-Miranda G, Allende-Monclus H. Probable early acute hepatitis with parenteral amiodarone. *Clin Cardiol* 1986;9:223-9.
- 8 Yagupsky P, Gazala E, Sofa S, Maor E, Abarbanel J. Fatal hepatic failure and encephalopathy associated with amiodarone therapy. *J Pediatr* 1985;107:967-70.
- 9 Rumessen JJ. Hepatotoxicity of amiodarone. *Acta Med Scand* 1986;219:235-9.